Filtering by:
FDACDC Warns Against Vaping During Lung Illness Investigation
Federal experts are investigating reports of severe lung illnesses in people who used e-cigarettes (also known as vaping).
FDA Approves Rozlytrek (Entrectinib) for Tumors With Certain Genetic Markers
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
FDA Reveals New Ads to Warn Kids About E-Cigarettes
The US Food and Drug Administration (FDA) is launching a new series of TV ads to teach kids about the dangers of using e-cigarettes.
FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First PI3K Inhibitor for Breast Cancer
The US Food and Drug Administration (FDA) has approved the first treatment of its kind for a certain type of breast cancer caused by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor.
FDA Approves First Targeted Therapy for Bladder Cancer
The US Food and Drug Administration (FDA) has approved Balversa (erdafitinib) as the first targeted therapy for bladder cancer.
FDA Approves Tecentriq (Atezolizumab) for Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
